Type II Kounis Syndrome Secondary to Amoxicillin Allergy Authors: Hrushikesh Reddy Pamreddy, Arihant Surana, Krishna Sagar Gajula, Usama Talib, Allen Filliberti Published: 2026 ABSTRACT AbstractBackgroundKounis syndrome is an under-recognized cause of acute coronary syndrome precipitated by allergic or anaphylactic reactions. Recognition is critical, as management requires simultaneous treatment of both conditions.Case SummaryA 64-year-old woman with cardiovascular risk factors developed anaphylaxis after amoxicillin ingestion. Despite treatment with epinephrine and corticosteroids, she developed chest pain, with electrocardiogram showing inferior ST-segment elevations. Emergent catheterization revealed an occluded mid right coronary artery with nonobstructive left coronary disease. Successful percutaneous intervention was performed with drug-eluting stent placement, consistent with type II Kounis syndrome.DiscussionThis case represents 1 of approximately 3 reported cases in the literature of type II Kounis syndrome in a female patient secondary to amoxicillin, highlighting the importance of cardiac vigilance during anaphylaxis management.Take-Home MessagesKounis syndrome should be suspected when chest pain develops during anaphylaxis, prompting urgent electrocardiographic evaluation. Management requires balancing conflicting therapies for anaphylaxis and acute coronary syndrome.Key words: anaphylaxis, coronary thrombosis, drug allergy, mast cell activation, myocardial infarction, percutaneous coronary intervention History of Presentation A 64-year-old woman presented to the emergency department with acute onset of tongue swelling, lip swelling, facial and hand erythema, burning sensation in her extremities, and progressive dyspnea. Symptoms began approximately 30 minutes after taking an amoxicillin pill for a groin rash. Shortly after symptom onset, she developed lightheadedness and began experiencing chest discomfort while on the way to the hospital. On arrival, vital signs revealed profound hypotension with blood pressure of 55/33 mm Hg, heart rate of 94 beats/min, respiratory rate of 21 breaths/min, and oxygen saturation of 96% on room air. Physical examination was notable for angioedema of the lips and tongue, diffuse cutaneous flushing, and mild respiratory distress. She was immediately treated for anaphylaxis with intramuscular epinephrine and intravenous methylprednisolone and diphenhydramine, with subsequent hemodynamic improvement. Past Medical History The patient's medical history was notable for type 2 diabetes mellitus, hypertension, hyperlipidemia, plantar fasciitis, and acquired left hallux valgus. She reported a known allergy to trimethoprim-sulfamethoxazole. She denied use of any regular medications despite her chronic conditions. Social history was significant for a 50 pack-year smoking history. She denied alcohol or recreational drug use. Of note, she had presented to the emergency department 6 months prior with chest pressure and mildly elevated troponin (20 ng/L), and she was advised to undergo further cardiac work-up but had left against medical advice. An outpatient echocardiogram performed 2 months later demonstrated normal left ventricular size and function, with an ejection fraction of 55% to 60% and no wall motion abnormalities, suggesting subclinical coronary disease. Differential Diagnosis Given the presenting symptoms, anaphylaxis was immediately recognized. However, the development of chest discomfort in this setting raised several considerations, such as type II Kounis syndrome (allergic mediator-induced plaque destabilization), demand ischemia secondary to hypotension, Takotsubo cardiomyopathy, and epinephrine-induced coronary vasospasm. Investigations Laboratory studies Initial laboratory evaluation was notable for metabolic acidosis (bicarbonate: 16 mEq/L, anion gap: 19, lactic acid: 4.4 mmol/L), hyperglycemia (glucose: 213 mg/dL), and an atherogenic lipid profile (low-density lipoprotein cholesterol: 154 mg/dL, high-density lipoprotein cholesterol: 41 mg/dL). Complete blood count, renal function, and liver enzymes were within normal limits. Serum tryptase, obtained approximately 90 minutes after symptom onset, was 7.6 ng/mL (reference: <11.4 ng/mL). Detailed laboratory values are provided in Supplemental Table 1. Electrocardiography The initial electrocardiogram (ECG) demonstrated normal sinus rhythm without acute ischemic changes. A repeat ECG obtained after the patient reported worsening chest pain revealed ST-segment elevations in leads II, III, aVF, and V6, with reciprocal ST-segment depressions in leads I, aVL, V2, and V4, consistent with acute inferior ST-segment elevation myocardial infarction (STEMI) with posterior involvement (Figure 1). Electrocardiogram Demonstrating Inferior STEMI Repeat electrocardiogram obtained after worsening chest pain showing ST-segment elevations in leads II, III, aVF, and V6, with reciprocal depressions in leads I, aVL, V2, and V4, consistent with acute inferior STEMI with posterior involvement. STEMI = ST-segment elevation myocardial infarction. Chest radiography Chest x-ray showed diffuse increased interstitial markings with a possible trace left pleural effusion. Echocardiography Postprocedural transthoracic echocardiography showed low-normal left ventricular systolic function (ejection fraction: 55%) with mild to moderate hypokinesis of the basal and midinferior and inferolateral segments. Right ventricular function was normal with no significant valvular disease or pericardial effusion. Management Emergency department management Upon recognition of anaphylaxis, the patient received immediate treatment with intramuscular epinephrine, intravenous methylprednisolone 125 mg, and intravenous diphenhydramine 50 mg. Intravenous fluid resuscitation was initiated for hypotension. When repeat ECG demonstrated ST-segment elevations consistent with inferior STEMI, a Code STEMI was activated. Given her known contrast allergy (prior reaction to iodinated contrast), she was premedicated with hydrocortisone and diphenhydramine before cardiac catheterization. Coronary angiography and intervention Emergent coronary angiography was performed via right radial arterial access (Figure 2). RCA Angiogram Revealing Mid-RCA Occlusion Coronary angiography demonstrating complete occlusion of the midsegment of the dominant RCA with TIMI flow grade 0. RCA = right coronary artery. Angiographic findings included the following: •Left main coronary artery: No significant stenosis. Left main coronary artery: No significant stenosis. •Left anterior descending artery: Nonobstructive disease. Left anterior descending artery: Nonobstructive disease. •Left circumflex artery: Nondominant vessel with nonobstructive disease. Left circumflex artery: Nondominant vessel with nonobstructive disease. •Right coronary artery (RCA): Dominant, occlusion of the midsegment with TIMI flow grade 0 antegrade flow. Right coronary artery (RCA): Dominant, occlusion of the midsegment with TIMI flow grade 0 antegrade flow. Successful percutaneous coronary intervention (PCI) of the mid-RCA was performed with implantation of a 3.5 × 48 mm everolimus-eluting stent, postdilated with a 3.75-mm noncompliant balloon catheter (Figure 3, Figure 4, Figure 5). Final angiography demonstrated an excellent result, with TIMI flow grade 3 (Figure 6). Left Coronary System Angiography Angiography of the left coronary system revealing nonobstructive disease in the left main, left anterior descending, and left circumflex arteries. Balloon Angioplasty of the Mid-RCA Predilatation with a 2.5 × 15 mm semicompliant balloon catheter followed by restoration of flow revealing the area of ruptured plaque. RCA = right coronary artery. Restoration of Flow After Balloon Angioplasty Angiography after predilatation revealing the area of ruptured plaque in the mid-RCA. RCA = right coronary artery. Final Angiographic Result After Stent Deployment Postdeployment angiography of the 3.5 × 48 mm everolimus-eluting stent demonstrating excellent result with TIMI flow grade 3 in the mid-RCA. RCA = right coronary artery. The patient experienced complete resolution of chest pain after intervention. Postprocedural ECG showed resolution of ST-segment elevations with development of T-wave inversions in the inferior leads, consistent with successful reperfusion. Postprocedural medical therapy The patient was initiated on guideline-directed medical therapy including aspirin 81 mg daily, ticagrelor 90 mg twice daily, atorvastatin 80 mg daily, valsartan 160 mg daily, and metoprolol succinate (dose titrated to heart rate). Postprocedural intravenous normal saline was administered at 100 mL/h for 4 hours for contrast-induced nephropathy prophylaxis. Outcome and Follow-Up The patient's postprocedural course was uncomplicated, with a hospital length of stay of 3 days. Her high anion gap metabolic acidosis and mild transaminitis, attributed to hypoperfusion during anaphylaxis, resolved with fluid resuscitation and restoration of coronary perfusion. Cardiac biomarkers demonstrated appropriate rise and fall, with creatine kinase–MB trending down from 202 to 63 ng/mL by hospital day 2, consistent with successful reperfusion (Table 1). Echocardiography on postprocedure day 1 confirmed preserved ejection fraction at 55% with regional wall motion abnormalities corresponding to the RCA territory. Table 1Cardiac Biomarker Kinetics During HospitalizationTime PointHigh-Sensitivity Troponin (ng/L)Creatine Kinase–MB (ng/mL)Day 1: Presentation92Day 1: Post-PCI7,202202Day 2—63PCI = percutaneous coronary intervention. Cardiac Biomarker Kinetics During Hospitalization PCI = percutaneous coronary intervention. The patient completed inpatient cardiac rehabilitation and was referred for outpatient cardiac rehabilitation. She was counseled on strict avoidance of amoxicillin and all penicillin-class antibiotics, with documentation in the medical record and provision of medical alert identification. Outpatient follow-up was arranged with cardiology, allergy/immunology, and primary care for cardiovascular risk-factor optimization and smoking cessation. Discussion Kounis syndrome, first described by Nicholas Kounis in 1991, refers to the concurrence of acute coronary syndrome (ACS) with allergic or hypersensitivity reactions, including anaphylaxis.1 The syndrome encompasses a spectrum of presentations classified into 3 variants: Type I occurs in patients with normal coronary arteries, where allergic mediators induce coronary vasospasm; type II occurs in patients with pre-existing atheromatous disease, where mediator release precipitates plaque erosion or rupture; and type III involves stent thrombosis triggered by hypersensitivity reactions.2, 3, 4 A systematic review of amoxicillin-induced Kounis syndrome identified only 33 cases reported in the literature from 1972 to May 2022, with a striking male predominance (81.8% male).5 Given that type II Kounis syndrome represents approximately 48% of all cases, and considering the male predominance, our case represents 1 of only approximately 3 reported cases of type II Kounis syndrome in a female patient secondary to amoxicillin.2 The pathophysiology involves inflammatory mediators such as histamine, leukotrienes, platelet-activating factor, and cytokines, which exert direct effects on the coronary vasculature and atherosclerotic plaque.1 Histamine promotes coronary vasoconstriction via H1 receptors and activates platelets. Mast cell–derived proteases can degrade the fibrous cap of vulnerable plaques, precipitating rupture.1,6 In the present case, the angiographic finding of acute mid-RCA occlusion with nonobstructive disease in the remaining coronary system, in the setting of systemic anaphylaxis, strongly supported allergic mediator-induced plaque destabilization. Serum tryptase in our patient was within normal limits (7.6 ng/mL); however, tryptase elevation is neither sensitive nor specific for Kounis syndrome, and the absence of a baseline level limits interpretation.7, 8, 9 An acute-to-baseline ratio exceeding 1.685 supports systemic mast cell activation.8,10 The clinical presentation and angiographic findings were diagnostic. Management of Kounis syndrome presents unique challenges, as therapies for anaphylaxis and ACS may have conflicting effects.11,12 Epinephrine may exacerbate coronary vasospasm, while beta-blockers may worsen bronchospasm. Our patient received epinephrine before STEMI recognition, and emergent revascularization was prioritized once diagnosed. Nicorandil, a coronary vasodilator with minimal hemodynamic effects, may be useful in Kounis syndrome with suspected vasospasm.11,13 In our case, complete thrombotic occlusion rather than isolated vasospasm made primary PCI the definitive treatment. The decision to proceed with catheterization despite a history of contrast allergy reflects the favorable risk-benefit ratio in the setting of ongoing STEMI. Clinicians must maintain vigilance for cardiac complications during anaphylaxis, as chest pain may be attributed to the allergic reaction itself rather than recognized as a distinct cardiac event. ECG should be obtained promptly in any patient with chest discomfort during anaphylaxis. Conclusions This case illustrates type II Kounis syndrome presenting as inferior STEMI in a patient with anaphylaxis secondary to amoxicillin. Prompt recognition and emergent PCI resulted in successful revascularization and a favorable outcome. Clinicians should maintain high suspicion for ACS when chest symptoms develop during allergic reactions, even in patients without known coronary artery disease. Case Timeline Flowchart illustrating the clinical progression from amoxicillin-induced anaphylaxis through STEMI recognition, emergent PCI, and recovery. BP = blood pressure; DES = drug-eluting stent; ECG = electrocardiogram; EF = ejection fraction; GDMT = guideline-directed medical therapy; PCI = percutaneous coronary intervention; RCA = right coronary artery; STEMI = ST-segment elevation myocardial infarction. Funding Support and Author Disclosures The authors have reported that they have no relationships relevant to the contents of this paper to disclose. Take-Home Messages •Kounis syndrome should be suspected when chest pain or hemodynamic instability persists during anaphylaxis treatment, prompting immediate ECG evaluation and cardiology consultation. Kounis syndrome should be suspected when chest pain or hemodynamic instability persists during anaphylaxis treatment, prompting immediate ECG evaluation and cardiology consultation. •Management of concurrent anaphylaxis and acute coronary syndrome requires careful balancing of potentially conflicting therapies, with primary PCI prioritized when STEMI is confirmed. Management of concurrent anaphylaxis and acute coronary syndrome requires careful balancing of potentially conflicting therapies, with primary PCI prioritized when STEMI is confirmed. Acknowledgments The authors thank all contributors and institutions supporting this work. Footnotes The authors attest they are in compliance with human studies committees and animal welfare regulations of the authors’ institutions and Food and Drug Administration guidelines, including patient consent where appropriate. For more information, visit the Author Center. Appendix For a supplemental table, please see the online version of this paper. Appendix Supplemental Table 1 Detailed Laboratory Values at Presentation References Associated Data Supplementary Materials Supplemental Table 1 Detailed Laboratory Values at Presentation